Login to Your Account



Alk-Abello targets China's growing allergy market, inks Eddingpharm deal

By Shannon Ellis
Staff Writer

Wednesday, April 30, 2014

SHANGHAI – Alk-Abello A/S has signed a deal in which up and comer specialty pharmaceutical, Eddingpharm Co. Ltd., will handle the sales and distribution of Alk's allergy immunotherapy treatment here, products it hs been selling under its own steam since 2005.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription